Moleculin Biotech, the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Sara Nik from H.C. Wainwright reiterated a Buy rating on the stock and has a $4.00 price target.
TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Sara Nik has given her Buy rating due to a combination of factors that highlight Moleculin Biotech’s strategic advancements and potential in the oncology field. The recent partnership with the University of North Carolina at Chapel Hill is a significant factor, as it underscores the broader potential of annamycin in treating pancreatic cancer. This collaboration not only enhances the visibility of Moleculin’s pipeline but also provides early-stage optionality, which could lead to substantial value addition.
Sara Nik also emphasizes the importance of the upcoming Phase 3 MIRACLE trial data readout for relapsed/refractory acute myeloid leukemia (r/r AML) patients, expected in the fourth quarter of 2025. Additionally, the planned investigator-initiated Phase 1b/2 study by Atlantic Health for annamycin in third-line pancreatic cancer further supports the positive outlook. The promising preclinical data demonstrating annamycin’s activity against pancreatic cancer and liver metastases adds to the confidence in Moleculin’s potential success and growth, justifying the Buy rating.